Acerta Pharma B.v.

Nodality, Inc.

Todd Covey

Wayne Philip Rothbaum

Tjeerd Barf

Brian Lannutti

Allard Kaptein

Ahmed Hamdy

Raquel Izumi

Roger G Ulrich

Dave Johnson

David B Rosen

Adam Palazzo

Norman Purvis

James Cordiero

David M Johnson

Roger Ulrich

Therapeutic methods of treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) are described. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating subtypes of CLL and SLL using a BTK inhibitor, including subtypes of CLL in patients sensitive to thrombosis and subtypes of CLL that increase monocytes and NK cells in peripheral blood after treatment with a BTK inhibitor. In certain embodiments, the invention includes therapeutic methods of treating CLL and SLL using a combination of a BTK inhibitor and an anti-CD20 antibody.

Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor

Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the &#x3b3;- and &#x3b4;-isoforms and selective for both &#x3b3;- and &#x3b4;-isoforms (PI3K-&#x3b3;,&#x3b4;, PI3K-&#x3b3;, and PI3K-&#x3b4;), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-&#x3b4; inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.

Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor

In some embodiments, the invention includes a therapeutic combination of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the &#x3b3;- and &#x3b4;-isoforms and selective for both &#x3b3;- and &#x3b4;-isoforms, and a Bruton's tyrosine kinase (BTK) inhibitor. In some embodiments, the invention includes therapeutic methods of using a BTK inhibitor and a PI3K-&#x3b4; inhibitor to treat solid tumor cancers by modulation of the tumor microenvironment, including macrophages, monocytes, mast cells, helper T cells, cytotoxic T cells, regulatory T cells, natural killer cells, myeloid-derived suppressor cells, regulatory B cells, neutrophils, dendritic cells, and fibroblasts.

Therapeutic combination of PI3K inhibitor and a BTK inhibitor

Therapeutic combinations of a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the &#x3b3;- and &#x3b4;-isoforms and selective for both &#x3b3;- and &#x3b4;-isoforms, are described. In some embodiments, the invention provides pharmaceutical compositions comprising combinations of (1) a PI3K-&#x3b4; inhibitor and a BTK inhibitor, (2) a JAK-2 inhibitor and a BTK inhibitor, or (3) a JAK-2 inhibitor, PI3K-&#x3b4; inhibitor, and BTK inhibitor, and methods of using the pharmaceutical compositions for treating a disease, in particular a cancer.

Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor

The invention provides systems, compositions, kits and methods for automated processing of biological samples and analysis using a flow cytometer.

High throughput flow cytometry system and method

Growing community of inventors

San Carlos, CA, United States of America

Todd Covey